TW397836B - Tumour localising photosensitising compounds - Google Patents

Tumour localising photosensitising compounds Download PDF

Info

Publication number
TW397836B
TW397836B TW084105690A TW84105690A TW397836B TW 397836 B TW397836 B TW 397836B TW 084105690 A TW084105690 A TW 084105690A TW 84105690 A TW84105690 A TW 84105690A TW 397836 B TW397836 B TW 397836B
Authority
TW
Taiwan
Prior art keywords
compound
compounds
tumor
group
standards
Prior art date
Application number
TW084105690A
Other languages
Chinese (zh)
Inventor
David Frederick Horrobin
Brenda Elizabeth Reynolds
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of TW397836B publication Critical patent/TW397836B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Improved tumour localisation of polyether-substituted photosensitising compounds is given leading to their more efficient uptake into turmour cells. Lower overall doses of drug give an improved side-effect profile of the treatment especially with regard to skin photosensitisation. Compounds being polyethylene glycol derivatised, pharmaceutically acceptable tumour locating dihydro or tetrahydro porphyrins of the formulae (3) and (4) wherein R1 may be partly hydroxyl but at least one chain of formula -O-X-[CH2CH2O]m-Y wherein m = 25 to 150; the group Y may be a C1-C4 alkyl group but preferably a methyl group and the group X is of formula (5).

Description

經濟部中央標準局員工消費合作社印製 A7 _ _B7_ 五、發明説明(1 ) 太發明係闞於聚乙醚-取代之慼光化合物及其治療腫瘤 之用法。 · 光力學療法包括投予感光化合物,接著再用一特定波長 之可見光照射含有該化合物的組織。所得活化化合物和氧 作闬形成活性自由基,其會引起周邊.姐織壞死。 本形式之成功與否端視於所投予之化合物和正常姐織比 較時,其選擇{生留在腫瘤姐織,而因此用可見光照射腫瘤 時,埭死賺瘤组織造成之破壞量會成比例地比£常组織中 的高。然而,一些IE常姐縛的傷害也可能發生且可見於使 闬許多感先劑的一涸特殊副作闬是暴露在E常光照標準 (特別是日光)的皮膚會紅腫(紅斑)。這霈要病人在治療 後保持栌纟S和之光線中數週,而此會限制其生活品質。將 該慼光化合物較有效的傳送至腫瘤姐織內,因而提供藥物 濃度在瞜額對正常皮虜之較高比值可戲劇性迪降低此療法 φ對皮慮副作m之可能性。 這積聘瘤定位也可用作判定腫瘤位置、大小等之診斷工 具,及其治療之選擇。某些感光劑若用做可偵側螢光之來 /薄則可作為診斷工具。此外,某些放射線-標記之實體也 可將之W λ診斷目的之腫瘤定泣用化合物。 先前有一群感光化合钧已涇是Ε Ρ (Π 3 7 β 0 1 A 1之主題。 這搜.1h合物為式Π.)之二氫樹> (克羅林Η,C h〖〇 r丨n s )及 逛其相當之式m的四氣< 啉(細爾克羅林茲): -4.- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 _ _B7_ V. Description of the invention (1) The invention of the invention is based on the use of polyether-substituted chiguang compounds and their use in the treatment of tumors. Photodynamic therapy involves administering a light-sensitive compound and then irradiating the tissue containing the compound with visible light of a specific wavelength. The resulting activated compound and oxygen act as osmium to form active free radicals, which can cause necrosis in the periphery. The success of this form depends on the comparison between the administered compound and the normal tissue, and its choice {to stay in the tumor tissue, and therefore when the tumor is irradiated with visible light, the amount of damage caused by strangulation and tumor formation will Proportionally higher than in regular organizations. However, some injuries caused by IE Changjie may also occur and can be seen in a special side effect of many prodrugs: skin exposed to the E light standard (especially daylight) will be red and swollen (erythema). This requires the patient to stay in the sun and light for several weeks after treatment, which can limit their quality of life. The Qiguang compound is more effectively delivered to the tumor tissue, and thus providing a higher ratio of drug concentration to the normal skin is able to dramatically reduce the possibility of this treatment φ for skin anemia. This accumulated tumor location can also be used as a diagnostic tool to determine the location and size of the tumor and its treatment options. Some photosensitizers can be used as diagnostic tools if used as detectable / thin fluorescent light. In addition, certain radiation-labeled entities can also be used to determine tumor compounds for Wλ diagnostic purposes. Previously, a group of photosensitizers He Jun has been the subject of ΕΡ (Π 3 7 β 0 1 A 1. This search. 1h compound is the formula Π.) Of the dihydro tree > (Crowling, C h 〖〇 r 丨 ns) and four equivalents of the equivalent formula m (Porphyrin): -4.- This paper size applies the Chinese National Standard (CNS) Λ4 specification (210X 297 mm) (please (Read the notes on the back before filling out this page)

五、發明説明(夕)V. Description of the invention (Eve)

kl B7kl B7

其中, 為正、 該取 可K是 δ岸闹罕 接受之 Π! ^ I» 紅色末 可知 類、戎 指昉醇 r pjt 經濟部中央標準局員工消費合作社印製 ja. 每個R為羥基 間或對位。 代基團在其個 自由的、取代 之烷基 ')。假 水基溶莪中之 哌给子以確定 端之光的吸收 -A-ί· ^PJSJ __ N :*:谭p丨再進一 h述任一'種該 其水合物或其 類)之彤式中 化S式中兩種 號碼(.N 〇 ) 團旦相對於連接至核心之笼環的位置 別苯*團上可在相同或不同位置,且 的或部分取代的(例如:用含有1至4個 設_理學上之耐受性、在藥理學上可 少許溶解度(為所需的,如此該藥物 其快速分布至腫瘤)、在可見光範圍 ,和癌姐纖中之吸收可Μ保持,則該 步將之取代。 化合物可存於其酸性或鹼性中心之鹽 他溶合物ί特別是與低烷(如:c t - c 4 ) 特定的化合物列於下表中: 表1 R 間 0H 間0 P; -----:--.---(\------訂------f V (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A7 B7 五、發明説明(9) 本發明係關於用有連接三嗪基團之聚乙二醇將式(1)、 (2)化合物的酚基羥基團衍生或部份衍生,其末端羥棊用 C t - C 4烷基i甲基團為最佳)醚化或酯化。型式(3 )和(4)化 合物中之结杲如下所示:Among them, it is positive, the deduction K is accepted by δ An Naohan! ^ I »The red end of the known, Rongzhi alcohol r pjt printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. Each R is a hydroxyl group. Or alignment. The radical is in its free, substituted alkyl '). Piperidine in Pseudo-water-based Solvent to determine the absorption of light at the end-A-ί · ^ PJSJ __N: *: Tan p 丨 one further description of any of these hydrates or their species) In the formula, the two numbers (.N 〇) in the formula S are relative to the position of the cage ring connected to the core. The benzene * group may be at the same or different positions, and may be partially or partially substituted (for example, by containing 1 To 4 physiological tolerances, a little solubility in pharmacology (as required, so that the drug quickly distributes to tumors), visible absorption, and absorption in cancer fibers can be maintained. Then this step will replace it. The compound can exist in the salt or other solvates of its acidic or basic center. Especially the compounds with low alkanes (such as: ct-c 4) are listed in the following table: Table 1 0H room 0 P; -----: --.--- (\ ------ order ------ f V (Please read the precautions on the back before filling this page) This paper size Applicable to China National Standard (CNS) A4 specification (210X297 mm) A7 B7 V. Description of the invention (9) The present invention relates to the use of polyethylene glycol with a triazine group to link compounds of formula (1) and (2). Phenolic hydroxyl Group derivatized or partially derivatized with its terminal hydroxyl Qi C t - C 4 alkyl group is methyl i optimum) etherified or esterified type (3) and (4) compounds in Gao knot as follows:

(4) (請先閲讀f'面之注意事項再填寫本頁) 其中,R 1可K部份是R但至少一者為鏈式-〇 - XP -[CH2CH20 ] «-Υ,其中 m = 5至 250。該基團 丫可 Μ 是 -1:4烷 «,柜Μ甲基團較佳。連接基團X為式(5)。(4) (Please read the precautions on the f 'side before filling out this page) Among them, the K part of R 1 may be R but at least one of them is chain-〇- XP-[CH2CH20] «-Υ, where m = 5 to 250. This group is a -1: 4 alkane «, preferably a methyl group. The linking group X is of formula (5).

,1T 經濟部中央標準局負工消費合作社印製, 1T Printed by the Consumer Standards Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs

O-iCHiCHjOJnjY (δ) 霖要扰兩棰S1?代之聚乙二醇_之至φ —平均必須連接至O-iCHiCHjOJnjY (δ) To interfere with the two S1 generations of polyethylene glycol_ to φ — the average must be connected to

(3) 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(</ ) 型式U)和(2)化合物;且較佳為每一鍵畏必須計蓴而能提 供型式(3 )和(4 )之總分子重量不少於5 0Ό 0道耳呑且不多 於2 (). 0 0 0道百呑。 在上列任一檑化合物中,可形成.無機酸(即,氡氯酸馥 、硫酸鹽等)之鹽類及水合物和用低烷(i: j - C 4 )醇類衍生之 ( 溶合物。所有的這類形式皆包括於此專利範圍中。 型式(3 )和(4)(其中,'此處之R定義如前所述)係藉由用 型式(:β)化合物('其中,m和Y眈處定義同前'1和型式(1)和 f 2 )化合物(其中,R呔琮定義同前)反遞RM下方式彤_ i . 於固鹼金鼷重破酸鹽或碳酸鹽存在下,催化量之 辩轉化觸媒f如十六烷基三甲基箝溴化物)和適當溶 劑(如丙_)於0至60 °c溫度下反應,之後加水再反 應。 π . 於飽和水性溶液螓金鼷竜碳酸鹽存在下,催化最之 相轉fb觸媒(如十六烷基三甲基銨溴化物)和適當非 永可绲合之溶劑(如二氡甲烷)於兩枏糸統於0至 ' 6 〇 in锶度下反應。 iii. 妒錄金鼷隼碳酸轉和水之琨合物存在下,適當水可 溶非羥溶劑{'如1,4-二瞟烷)於 <)至40 T:潙度下反應 該衍e之二氧筘西氧C2卜瞅彳h合均ί 3 )和(4)有下列性暫: ! . ?R溶件捎加。 2 -泎騁肉之竭琿時問較馬。 -----:-- ------^ 衣------訂-----、線 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(i) •3.键结罕血笱蛋内的增加。 λ .轺a體.fb合物比較時,腾瘤的累積速+_率增加。. 5 .皮痛的感光作用減少。 和衍牛.之啉(如揭示於W im / 1 8 R 3 0 ( D K. Z ')丨n t e r a Π a的)比較時,聚乙二_衍生之四-(3 -羥基笼基)克羅林 茲ί 3)在各種動物腾瘤槙式中與其母體藥物比較起來,其 已顯示促進腫瘤濃縮性質至令人繁奇的程度。 化合物(3 )和(4 ),光譜中可見光範圍之發色圑對於相應 化合物〇 )及(2 )而言並未.改變,化合物>(3 )和(4)之平均分 子最抝下式所示: 舉例而言化合物(3a): (U)之 MW-(la)之 於 650 nm 荜均分平鼍(3 a ) =__ ί 3 3 )之 A 1 妬於 β 5 0 n in 該If侈式已嬅由二氫 口卜 酚和細阑二氫酚之聚乙烯衍生 物的蚤子分析及潮最已回收未衍生物®之最所確認。 甯例1 楫同f| H®祿氫納u 7部分)加至7 , 8 -二氫-四-5,1 0,1 5, 2 () - ί 3 ·-锊荣基)叶1« (1 3,丨部分)、三甲基+六烷基铵溴化 物《+0 · 1部分)和化合物Ua . R1具B = 35-55, Y = CH3 . 16部分)於 丙_ (300部分1之溶務中,於20-25T:下欖袢混合物15-24 小時。於真空中移去丙嗣,加入永(4 0 0部分)之後再搜拌 漼合物1 -2小時。冷凍乾燁渴合物,之後K二氛甲烷(400 部分)欖捽,K過濾移去不可溶之納篛◊於真空中移出二 I----'--------------訂-----K鉍 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 397836 a? B7 五、發明説明(to 氯甲烷,將殘留物再溶於水(100部分)中.,於0DS3逆相矽 P管柱(400部分)中Μ水為溶析液進,行色譜分析=而棕色 部份目.11經0.2 /ί I«過癉器過濾Μ移除粒子,且冷凍乾燦而產 生棕色非结晶粉末(3 a,R 1具m = 3 5 - 5 5,Y = C Η 3,8 - 1 0部分'! ,πι . η . 5 0 -55 ^ » M W ( K fcb I? II V ) = 7 5 0 0 - 8 0 0 0 - II V = λ …: ; 4 16 nm (Al0^ = 1 5 0.7 ) * 5 20 n m ( A 1 = 2 0 . 4) * 5 48 n in ( A ] % =ί 5 . 2 ),5 Q 8 n ro ( A 1 94 = 8 '· 1 ),6 5 2 n m ( A 1 %' = 4 0 - 4 .)。而每 衹次之搡作中A值會有稍微比例之改變。 3 a Μ Η P丨(] P C顯示包含-3族化合物,廊 (請先閱讀背面之注意事項再填寫本頁) 人 •W 4 4R : 【键 7 0 - 8 0 % 3 s / 3 3R : 1 5 - 2 0 % 3a/2 2 R 1 _ 5 - 1 0 % 經濟部中央標準局員工消費合作社印製 再次操作t述物質產生具全部3 a / 4,m . p . 5 0 - 5 5 Π, MW(W 比較丨丨 V)=8000-8500。 將 7,8 -二氫-四-5,1 (K 15,2 0 - ( 3,-羥茏基 W 卜啉(1 a ) Μ 相 當量之7 , ,1 7,U -四氫-四-5,1 0,1 Γ),2 0 - ( 3,-羥茏基)ρ卜啉 (2 a )替代,而製得(4 a,R 1 具 m = 3 5 - 5 5 . Y = (: Η 3 . 8 - 1 0 部分) ,ra . d . 5 0 - 5 Vn,tU! ( Μ 比較 Ιί V ) = 7 5 ⑼-8 0 0 0。Π V : 3 5 6 nmUl 嗥=196.8). 373 nm(Al%=19U5),522 = . 742 =〗16. 1)。再每衹次中A倩會有稍激 hh例之改琴。备物(48)之化合物分佈近似與上述(3a )中所 潮丨溴者。元孝分析:N揮論2.5-2.9¾,實際测得2.6%。對於N 之泪琀計:!;園丨侈某於聚乙二醇璉2 0 0 0 (即m = 4 5 )和連接2 . 3 訂 線 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 397838 g77五、發明説明(y) 或4 sit種_之平均分子量。 實例2 ‘將飽和碳酸氫納水溶液(1 7部分)加至7,8 -二氫-四 -5 , 1 0 . 1 5,2 0 - ( 3,-羥苯基)v卜啉(1 a,1部分)於三甲基十六 烷基铵溴化物(〇 . 1部分)和化合物((5 a , R 1具 m = 3 5 - 5 5 , Y = C Η 3 . 1 β部分)於二氯甲综·( 2 0 0部分)之溶液中之 懸浮液*於20-25 t下快速攪拌兩相涫合物15-24小時。於 真空中移去二氯甲烷,加入水(3 0 0部分)之後再攪拌混合 物1_ - 2小時。冷凍乾燦蒗合.物,之後K二:氡甲烷(4 0 0部分 '!搜拌,K過溥移去不可溶之納·鹽。於真空中移出二氯甲 烷,將殘留物再溶於水(200部分)中*於C1DS3逆相矽膠管 杵(8 0 0部分)中Μ水為溶析液進行色譜分析。而棕色部份 則羥0.2 am過濟器過濾W移除粒子* a冷凍乾烽而產生棕 色非结晶粉末(3 a,R 1具hi = 3 5 - 5 5,Y = C Η 3 . 6 - 1 0部分), m . d . 5 0 - 5 5 Ό,|·ί ΙΠ Μ 比較丨 ί V ) = 5 0 0 0 - 8 0 0 0。發現此種製備 之化合物分佈與規構有闞,於非常小規模(100 mg)產物中 ,則含較實例1為高比例之3 a / 4 ;然而,於超過4S產物 'MW〜5000時,刖含較大比例之3a/3及3a/2和甚至僅具一聚 氧乙烯_之3 a / 1化合物。 奮例2 搏 7 , S -二氫-四-5,1 0,1 5,2 0 - ( 3 ’ -羥笼基)啉(1 a,1 部 分)之溶液,和fb合物(Γ) a , R 1具m = 3 5 - 5 5 . Y = C Η 3,1 β部分)於 二聘垸ί 2 0 0部分)和水溶性碳酸氫納(5部分於2 0 0部分水中 ),於20-25'm "F攪样15-24小時。冷凍乾燁混合物,之後 (請先閱讀背面之注意事項再填寫本頁) 、-° 線 -10- 本紙張尺度適用中國國家標隼(CNS )八4規格(210 X 297公釐) 經濟部中央標準局員工消費合作社印製 391836 a7 B7 五、發明説明(J ) K 二 氛 烷 U 0 0部 分)攪拌,K過滹移去不可溶之納鹽。 於 真 空 中 移 出二氛 甲烷,將殘留物再 溶於水(2 0 0部分)中 1 乙 酸 乙 酯(2 X 20 0部分)萃取於0DS3逆相矽膠管柱 i S 0 0 部 分 )中Μ水為溶析液進行色譜分析。而棕色部份刖 經 0 . 2 11 ΪΏ 過 滹器過 濾K移除粒子,且 冷凍乾燥而產生棕色 非 结 晶 粉 末 (3a s R 1 具 m = 3 5 - 5 5,Y = C Η 3 ,4 - 6 部分)* m . p · 5 0 -5 f. < 1 Μ W f M bb 較 ijV)、三5000-6500 ( ) 3 a 之 樣 品 Κ Η P L C / P C顯示包含4族 化合物,即 3 a /4 4R 1 鍵- 40-60% 3 a /3 3R1键 2 0 - 3 0 % 3 a /2 2R 1鏈 20 -30¾ 3a /1 1R1鏈 0-10¾ fc 方 法 產 生較大 變化之產物分怖。 Μ 相 U 方 式進行 ,但將(6a) K相當 量(6b,R1具 m = 100- 120 . y = ch3 )替代而製得(3 b , R 1 具 ir = 100-120, Y = CH 3 * S -10部分) ,m · p · 5 2 - 5 7 10,M W ( Μ 比較 1] \Π = ί Ο Ο Ο Ο - 1 2 Ο Ο 0。ij V :蝰極值與3 a相同但強度較低。 -11 - -----.--r---^ ^------訂-----h 级 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)(3) This paper size applies Chinese National Standards (CNS > A4 size (210X297 mm). Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. A7 B7. 5. Description of the invention (< /) Type U) and (2) Compounds. ; And preferably, each key must be counted and can provide the total molecular weight of types (3) and (4) not less than 50 0 0 ears and not more than 2 (). 0 0 0 道 百 呑. In any of the above compounds, it is possible to form salts and hydrates of inorganic acids (ie, europium chlorochlorate, sulfate, etc.) and derivatized with low-alkane (i: j-C 4) alcohols ( All such forms are included in the scope of this patent. Forms (3) and (4) (wherein 'R is defined as previously described) are obtained by using the form (: β) compound (' Among them, the definitions at m and Y 眈 are the same as those of the former '1 and the formula (1) and f 2) (wherein, R 呔 琮 is the same as above). In the presence of carbonate, a catalytic amount of a catalytic conversion catalyst such as cetyltrimethyl clamp bromide and a suitable solvent (such as propylene) are reacted at a temperature of 0 to 60 ° C, and then reacted by adding water. π. In the presence of a saturated aqueous solution of osmium carbonate, it catalyzes the most phase-inverted fb catalyst (such as cetyltrimethylammonium bromide) and a suitable non-permanently compatible solvent (such as dioxane ) Reaction in the two systems at strontium degrees from 0 to '600 in. iii. In the presence of a mixture of carbonic acid and water, a suitable water-soluble non-hydroxyl solvent {'such as 1,4-dioxane) is reacted at <) to 40 T: The combination of the two oxygen oxoxox C2 and oxh 3) and (4) has the following temporary effects:! 2-Ask Bima when the meat is exhausted. ----- :------- ^ clothing ------ order ----- 、 line (please read the precautions on the back before filling this page) This paper size applies Chinese national standard (CNS) A4 size (210X297 mm) A7 B7 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (i) • 3. Increase in the number of eggs in the blood. When the λ. 轺 a.fb compound is compared, the cumulative rate of tumor growth + rate increases. 5. Reduced photosensitivity of skin pain. When compared with Yanniu's morpholine (as disclosed in Wim / 1 8 R 3 0 (D K. Z ') 丨 ntera Π a), polyethylene_derivative tetra- (3-hydroxycagel) g Rollinz 3) It has been shown to promote tumor-concentrating properties to an astonishing degree when compared to its parent drug in various animal tumor tumors. For compounds (3) and (4), the color in the visible light range in the spectrum is not changed for the corresponding compounds 0) and (2). The average molecular weight of compounds > (3) and (4) has the following formula: Shown: For example, compound (3a): (U) 's MW- (la)' s at 650 nm 荜 evenly divided 鼍 (3 a) = __ ί 3 3) A 1 jealous of β 5 0 n in If luxury has been confirmed by the flea analysis of the polyethylene derivatives of dihydrocaprofen and pilohydrophenol and the most confirmed by the recovered underivatized ®.宁 例 1 楫 Same f | H® Luhydrona u 7)) to 7, 8 -dihydro-tetra-5,1 0,1 5,2 ()-ί 3 ·-锊 荣 基) leaf 1 « (Parts 1 and 3), trimethyl + hexaalkylammonium bromide (part +0 · 1), and compound Ua. R1 has B = 35-55, Y = CH3. 16) in C (part 300) In the solution of 1, at 20-25T: the mixture of simmered linseed for 15-24 hours. Remove propane in vacuum, add yong (part 400), and then search for the mixture for 1-2 hours. Freeze-dried After the thirsty compound, K 2 methane (400 parts) is removed, K is filtered to remove the insoluble sodium, and 2 is removed in a vacuum. I ----'------------ --Order ----- K Bismuth (Please read the notes on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) 397836 a? B7 V. Description of the invention (to Methyl chloride, the residue was re-dissolved in water (100 parts), and the water in the 0DS3 reverse-phase silica P column (400 parts) was used as the eluent. Chromatographic analysis = and the brown part. 0.2 / ί I «filtered through a filter to remove particles, and freeze-dried to produce a brown amorphous powder (3 a, R 1 With m = 3 5-5 5, Y = C Η 3, 8-10 0 part '!, Π. Η. 5 0 -55 ^ »MW (K fcb I? II V) = 7 5 0 0-8 0 0 0-II V = λ :: 4 16 nm (Al0 ^ = 1 5 0.7) * 5 20 nm (A 1 = 2 0. 4) * 5 48 n in (A]% = ί 5. 2), 5 Q 8 n ro (A 1 94 = 8 '· 1), 6 5 2 nm (A 1%' = 4 0-4.), And the A value will change slightly in each subsequent operation. 3 a Μ Η P 丨 (] PC display contains Group-3 compounds, gallery (please read the precautions on the back before filling out this page) People • W 4 4R: [Key 7 0-8 0% 3 s / 3 3R: 1 5-2 0% 3a / 2 2 R 1 _ 5-1 0% Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs and re-operating the above-mentioned substance generators 3 a / 4, m. P. 5 0-5 5 Π, MW (W comparison 丨 丨 V) = 8000-8500. The 7,8-dihydro-tetra-5,1 (K 15,2 0-(3, -hydroxyfluorenyl W oxoline (1 a)) M The equivalent amount of 7,, 1,7, U -tetrahydro-tetra-5,1,0,1 Γ), 2-(3, -hydroxyfluorenyl) ρoline (2 a) was substituted to obtain (4 a, R 1 with m = 3 5-5 5. Y = (: Η 3. 8-10 part), ra. d. 5 0-5 Vn, tU! (Μ ratio Ιί V) = 7 5 ⑼-8 0 0 0. Π V: 3 5 6 nmUl 嗥 = 196.8). 373 nm (Al% = 19U5), 522 =. 742 =〗 16. 1). In each case, Aqian will revise the case slightly. The compound distribution of preparation (48) is similar to that of bromine in (3a) above. Analysis of Yuan Xiao: N talked about 2.5-2.9¾, and actually measured 2.6%. For the Tears of N :! ; Park 丨 luxury in polyethylene glycol 2 0 0 0 (that is, m = 4 5) and the connection 2.3 The size of this paper applies the Chinese National Standard (CNS) A4 specification (210X297 mm) Central Standard of the Ministry of Economic Affairs Bureau of the Consumer Cooperatives printed 397838 g77 V. Description of invention (y) or the average molecular weight of 4 sit species. Example 2 'Add a saturated aqueous solution of sodium bicarbonate (part 17) to 7,8-dihydro-tetra-5, 1 0. 1 5,2 0-(3, -hydroxyphenyl) v ibuline (1 a , Part 1) in trimethylhexadecyl ammonium bromide (part 0.1) and compounds ((5 a, R 1 with m = 3 5-5 5, Y = C Η 3.1 β part) in Dichloromethane · (suspension in part 200) solution * Suspend the two-phase mixture at 20-25 t for 15-24 hours. Remove the dichloromethane in vacuum and add water (3 0 Part 0), and then stir the mixture for 1_-2 hours. Freeze-drying the mixture, then K2: 氡 methane (4 0 0 '! Search and stir, K over to remove insoluble sodium salt. Under vacuum Dichloromethane was removed from the solution, and the residue was redissolved in water (200 parts) *. Chromatographic analysis was carried out in a C1DS3 reverse-phase silica gel tube pestle (800 parts) with M water as the eluent. The brown part was hydroxyl 0.2. Am filter to remove particles * a freeze-dried and produce brown amorphous powder (3 a, R 1 with hi = 3 5-5 5, Y = C Η 3.6-10 part), m. d. 5 0-5 5 Ό, | · ί ΙΠ Μ comparison 丨 ί V) = 5 0 0 0-8 0 0 0. It is found that the distribution and structure of the compound prepared by this method are very different. In a very small-scale (100 mg) product, it contains a higher ratio of 3 a / 4 than that of Example 1; however, it exceeds 4S product 'MW ~ 5000 At the same time, it contains a large proportion of 3a / 3 and 3a / 2 and even 3a / 1 compounds with only one polyoxyethylene. Example 2 Beat 7, S-Dihydro-tetra-5, 1 0, 1 5, 2 0-(3 '-hydroxycryl) line (1 a, 1 part) solution, and fb compound (Γ) a, R 1 with m = 3 5-5 5. Y = C Η 3, Part 1 β) Yu Erpin (part 2 0 0) and water-soluble sodium bicarbonate (part 5 in part 200 water), stir the sample at 20-25'm " F for 15-24 hours. Freeze and dry the mixture, and then (please read the precautions on the back before filling this page),-° line -10- This paper size applies to China National Standard (CNS) 8-4 (210 X 297 mm) Central Ministry of Economic Affairs Printed by the Consumer Cooperatives of the Standards Bureau 391836 a7 B7 V. Description of the invention (J) Part K 0 of the dibenzoxane is stirred, and K is removed to remove the insoluble sodium salt. Dichloromethane was removed in vacuo, and the residue was redissolved in water (part 200). 1 ethyl acetate (part 2 x 20 0) was extracted in 0DS3 reverse phase silica gel column (part S 0 0). Chromatographic analysis of the eluate. The brown part was filtered through 0.22ΪΏ to remove particles through a filter, and freeze-dried to produce a brown amorphous powder (3a s R 1 with m = 3 5-5 5, Y = C Η 3, 4 -6 parts) * m. P · 5 0 -5 f. ≪ 1 MW W f M bb compared to ijV), three 5000-6500 () 3 a sample K Η PLC / PC display contains group 4 compounds, ie 3 a / 4 4R 1 bond-40-60% 3 a / 3 3R1 bond 2 0-3 0% 3 a / 2 2R 1 chain 20 -30¾ 3a / 1 1R1 chain 0-10¾ fc terror. Phase M is performed in U mode, but (6a) K equivalent (6b, R1 with m = 100-120. Y = ch3) is substituted (3b, R1 with ir = 100-120, Y = CH3) * S -10 part), m · p · 5 2-5 7 10, MW (Μ comparison 1) \ Π = ί Ο Ο Ο Ο-1 2 Ο Ο 0. ij V: the extremum value is the same as 3 a but Low strength. -11------.-- r --- ^ ^ -------- Order ----- h (please read the precautions on the back before filling this page) Applicable to China National Standard (CNS) A4 specification (210X297 mm)

Claims (1)

A8 B8 C8 D8A8 B8 C8 D8 一種化合物,其係為聚乙二醇所衍生、藥理學上可接受 的、腫瘤定位用之二氫或四璧Q啉,其具有式(3)和 « 4 )A compound derived from polyethylene glycol, a pharmacologically acceptable dihydro or tetrafluorene Q morpholine for tumor localization, and having the formulae (3) and «4) (3)(3) (4) 其中,R 1可部份為羥基,但至少一鍵係式-0 - X -[ CH2CH2 0 U-Y * 其中 m = 25至 150 ;該基團 Y 可為 “-f:. 烷基,但以甲基較佳;該連结基團X為式(5)。 N NH N (5)(4) wherein R 1 may be a hydroxyl group, but at least one bond is -0-X-[CH2CH2 0 UY * where m = 25 to 150; the group Y may be "-f :. alkyl, But methyl is preferred; the linking group X is represented by formula (5). N NH N (5) (請先閱讀背面之注意事項再填寫本頁) 訂 線 經濟部中央標準局貝工消費合作社印袈 根據申請專利範圍第1項之化合物,其係作成衍生物 其係以無機酸使其作成鹽酸鹽、硫酸鹽等;或用低碳 ί C,- C 4 )醇類使其作成水合物或溶劑合物。 12 本紙張尺度適用中國國家梯準(CNS )八4规格(210Χ297公釐) 39 辦 6 ?! D8____一 專利範圍 一種利用式(3 )和.(4)之化物製造用於治療容易壞死之腾 ,i - * 瘤用藥劑之方法,其係將此種化合物投予而定位在該腫 •餺上,接著用該化合物所吸收波畏之可見光照射該腫瘤 ,該方法係藉由合併藥學稀釋劑或載劑和該化合物來使 用0 ' ' , 根撺申請專利範圍第1或2項之化合物,其中該化合物 4 * (3) 和(4)之分子量是5,000道耳呑至2〇, 〇〇〇道耳吞。 . 根據申請專利範圍第3項之方法’其中該化合物(3)和 5 · (4) 之分子量是5,000道耳呑至2〇,〇Ό〇道耳呑。 ί^-- (请先閱饋背面之.注意ί項再填寫本頁) 線 經濟部中央搮準局®?工消费合作社印«. 本紙張尺度適用中國國家梂準(CNS ) Α4規格(210X2S»7公釐)(Please read the precautions on the back before filling out this page.) The compound printed by the Central Bureau of Standards of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, according to item 1 of the scope of patent application, is a derivative, and it is a salt made of an inorganic acid. Acid salts, sulfates, etc .; or they can be made into hydrates or solvates with low-carbon C, -C4) alcohols. 12 This paper size is applicable to China National Standards of Standards (CNS) 8.4 (210 × 297 mm) 39 Office 6?! D8 ____ One patent scope a chemical compound manufactured using the formulas (3) and. (4) is used to treat the easily necrotic Teng, i-* A method for tumor drugs, which involves administering this compound to localize the tumor, and then irradiating the tumor with visible light absorbed by the compound, the method is by combining pharmaceutical dilution Agent or carrier and the compound to use 0 '', according to the compounds in the scope of patent application No. 1 or 2, wherein the molecular weight of the compound 4 * (3) and (4) is 5,000 ears to 20,000. 〇〇 Road ear swallow. The method according to item 3 of the scope of patent application, wherein the molecular weights of the compounds (3) and 5 · (4) are 5,000 to 20,000. ί ^-(Please read the back of the feed first. Note the ί item before filling out this page) Printed by the Central Bureau of Standards of the Ministry of Economic Affairs® Industrial and Commercial Cooperatives «. This paper size applies to China National Standards (CNS) Α4 specifications (210X2S »7 mm)
TW084105690A 1994-05-03 1995-06-06 Tumour localising photosensitising compounds TW397836B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408746A GB9408746D0 (en) 1994-05-03 1994-05-03 Tumour locallising photosensitising compounds

Publications (1)

Publication Number Publication Date
TW397836B true TW397836B (en) 2000-07-11

Family

ID=10754481

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084105690A TW397836B (en) 1994-05-03 1995-06-06 Tumour localising photosensitising compounds

Country Status (11)

Country Link
EP (1) EP0758331A1 (en)
JP (1) JPH09512544A (en)
KR (1) KR970702862A (en)
AU (1) AU2317295A (en)
CA (1) CA2189435A1 (en)
GB (1) GB9408746D0 (en)
NO (1) NO964635L (en)
NZ (1) NZ284552A (en)
TW (1) TW397836B (en)
WO (1) WO1995029915A1 (en)
ZA (1) ZA953560B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715591A (en) * 2018-06-01 2018-10-30 华东理工大学 Near infrared absorption porphyrin compound as photosensitizer and its application

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362175B1 (en) 1991-09-20 2002-03-26 The Trustees Of The University Of Pennsylvania Porphyrin compounds for imaging tissue oxygen
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
DE19627164C2 (en) * 1996-07-05 1998-09-24 Deutsches Krebsforsch Production of polyether-containing chlorins and bacteriochlorins, such compounds and their use
CA2341507C (en) 1998-08-28 2011-05-24 William Guy Love Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
GB0005855D0 (en) * 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
JP5000050B2 (en) * 2001-08-31 2012-08-15 浩 前田 Antitumor agent and method for producing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
GB8805849D0 (en) * 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
WO1991018630A1 (en) * 1990-05-30 1991-12-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polyether-substituted tumor agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715591A (en) * 2018-06-01 2018-10-30 华东理工大学 Near infrared absorption porphyrin compound as photosensitizer and its application

Also Published As

Publication number Publication date
NO964635D0 (en) 1996-11-01
NZ284552A (en) 1997-12-19
ZA953560B (en) 1996-01-11
CA2189435A1 (en) 1995-11-09
NO964635L (en) 1996-11-01
JPH09512544A (en) 1997-12-16
WO1995029915A1 (en) 1995-11-09
EP0758331A1 (en) 1997-02-19
GB9408746D0 (en) 1994-06-22
KR970702862A (en) 1997-06-10
AU2317295A (en) 1995-11-29

Similar Documents

Publication Publication Date Title
US4312883A (en) Furocoumarin for the photochemotherapy of psoriasis and related skin diseases
Van Henegouwen Medicinal photochemistry: phototoxic and phototherapeutic aspects of drugs
TW397836B (en) Tumour localising photosensitising compounds
Johnson Short Papers: Cellular Mechanisms of Chlorpromazine Photosensitivity
US20060040912A1 (en) Compounds for pdt
WO2021143829A1 (en) Non-peripheral quaternary ammonium group modified zinc phthalocyanine and method for preparation thereof and application thereof
JPH0764728B2 (en) Novel tetrapyrrole pharmaceutical composition
US7276494B2 (en) Photosensitisers
JPH07233065A (en) Photochemical therapeutic agent containing pyrylium salt or pyrylium analog salt
US6770787B2 (en) Heavier halogen atom substituted squaraine based dyes, process for the preparation thereof and use thereof as sensitizers for photodynamic, therapeutical and industrial applications
JPH0466873B2 (en)
EP1476190B1 (en) Amino-substituted hypocrellins for use as sonosensitizers
CN109160957B (en) Zinc phthalocyanine-chitosan oligosaccharide conjugate and preparation method and application thereof
JPS62167783A (en) Porphyrin derivative
JP6940979B2 (en) Ultrasonic sensitizer
US20200079906A1 (en) Photodynamic therapy complex
KR102696348B1 (en) Hypericin-PVP complex with high hypericin content
US20030087947A1 (en) Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photodynamic therapy
Morgan et al. Pentamethylpyrromethene boron difluoride complexes in human ovarian cancer photodynamic therapy
JP7084740B2 (en) Drug complexes, micelles, and pharmaceutical compositions
KR20180013368A (en) Porphyrin derivative having hydrophilic group and hydrophobic group, and process for preparing the same
JPS61122254A (en) Novel bis-(substituted amino)anthraquins
RU2548726C2 (en) Photosensitiser for photodynamic therapy
KR101620577B1 (en) Acne therapeutics and sebum secernent inhibitor containing chlorin derivatives, and kits for photodynamic therapy including the same
CN117731774A (en) Application of 3',4', 7-O-trimethyl luteolin in preparation of photodynamic therapy photosensitizer